Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pomalidomide in Systemic Sclerosis-Associated Interstitial Lung Disease
2010-023047-15Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2011
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing Pomalidomide with Placebo (2 arms). Primary endpoints: Safety and tolerability of pomalidomide versus placebo and Pharmacokinetics of pomalidomide. Started Dec 2011; status: terminated.
02
Drugs
pomalidomide
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2010-023047-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023047-15.